---
document_datetime: 2025-10-21 10:27:51
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/bimervax-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: bimervax-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.1581655
conversion_datetime: 2025-12-15 00:07:20.191953
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## BIMERVAX

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number                    | Scope                                                                                                                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                         |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------------------------------------|
| Variation type II / EMA/VR/0000257408 | C.I.6 Change(s) to therapeutic indication(s) - C.I.6.a Addition of a new therapeutic indication or modification of an approved one | 18/09/2025                          | 02/10/2025                                  | SmPC and PL                      | Please refer to Scientific Discussion 'Bimervax-VR- 0000257408' |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                                       | - Accepted Extension of indication to include the use of BIMERVAX in adolescents aged 12 years and above, based on interim results from the ongoing study HIPRA-HH-3. HIPRA-HH-3 is an open-label, multi-centre, non-inferiority study to assess the safety and immunogenicity of BIMERVAX as heterologous booster for the prevention of COVID-19 in adolescents from 12 years of age to less than 18 years of age. As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Furthermore, the PI is brought in line with   |            |            |                        |                                                                                                                   |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------------------------------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000279224 | This was an application for a group of variations. B.II.e.5.a Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - B.II.e.5.a.2 Change outside the range of the currently approved pack sizes - Accepted B.I.a.6 Changes to the active substance of a vaccine against human coronavirus - B.I.a.6.a Replacement or addition of a serotype, strain, antigen or coding sequence or combination of serotypes, strains, antigens or coding sequences for a human                                                                                                          | 18/09/2025 | 19/09/2025 | SmPC, Labelling and PL | Addition of a new strain (Omicron LP.8.1) resulting in three new monovalent presentations (EU/1/22/1709/008-010). |

<div style=\"page-break-after: always\"></div>

|                                       | coronavirus vaccine - Accepted B.II.e.5.a Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - B.II.e.5.a.1 Change within the range of the currently approved pack sizes - Accepted B.II.e.5.a Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - B.II.e.5.a.1 Change within the range of the currently approved pack sizes - Accepted                                                                                                                                                                                                                                                                                     |            |     |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type II / EMA/VR/0000262308 | C.I.11 Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.b Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment by the competent authority is required* - Accepted Submission of an updated RMP version 2.0 in order to remove one category 3 study (C- VIPER PASS), to include changes to the due date for the provision of the final study report for two category 3 studies (VAC4EU PASS, VAC4EU PAES) and to add BIMERVAX XBB.1.16 (Omicron XBB.1.16-adapted BIMERVAX). | 05/06/2025 | N/A |

<div style=\"page-break-after: always\"></div>

| Variation type IB / EMA/VR/0000269056   | B.II.f.1.b Extension of the shelf life of the finished product - B.II.f.1.b.5 Extension of the shelf-life of a biological/ immunological medicinal product in accordance with an approved stability protocol - Accepted   | 23/05/2025   | 19/09/2025   | SmPC   |
|-----------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------|